<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mitomycin (intravenous and intravesical) (systemic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mitomycin (intravenous and intravesical) (systemic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Mitomycin (intravenous and intravesical) (systemic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="83356" href="/d/html/83356.html" rel="external">see "Mitomycin (intravenous and intravesical) (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F13895008"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Experienced physician:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Mitomycin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Bone marrow suppression, notably thrombocytopenia and leukopenia, which may contribute to overwhelming infections in an already compromised patient, is the most common and severe of the toxic effects of mitomycin.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hemolytic uremic syndrome: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hemolytic uremic syndrome (HUS), a serious complication of chemotherapy, consisting primarily of microangiopathic hemolytic anemia, thrombocytopenia, and irreversible renal failure has been reported in patients receiving systemic mitomycin. The syndrome may occur at any time during systemic therapy with mitomycin as a single agent or in combination with other cytotoxic drugs; however, most cases occur at doses greater than or equal to 60 mg of mitomycin. Blood product transfusion may exacerbate the symptoms associated with this syndrome. The incidence of the syndrome has not been defined.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F51151365"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Mutamycin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F13895019"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Antibiotic</li></ul></div>
<div class="block doa drugH1Div" id="F13895060"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Do <b>NOT</b> substitute mitomycin injection for mitomycin (ureteral gel) or mitomycin (ophthalmic) or vice versa; the products are different and are <b>NOT </b>interchangeable.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1dbb6447-35bc-49b2-826f-4e8b8b0cdaa6">Anal carcinoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b> Anal carcinoma (off-label use):</b>
<b>IV:</b> 10 mg/m<sup>2</sup> as an IV bolus on days 1 and 29 (maximum: 20 mg/dose) in combination with fluorouracil and radiation therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18430910','lexi-content-ref-8823332']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18430910','lexi-content-ref-8823332'])">Ref</a></span>) <b>or</b> 12 mg/m<sup>2</sup> on day 1 only (maximum: 20 mg/dose) in combination with fluorouracil and radiation therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23578724','lexi-content-ref-20354531','lexi-content-ref-8874455']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23578724','lexi-content-ref-20354531','lexi-content-ref-8874455'])">Ref</a></span>) <b>or</b> 15 mg/m<sup>2</sup> on day 1 only in combination with fluorouracil and radiation therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9164216']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9164216'])">Ref</a></span>) <b>or</b> 10 mg/m<sup>2</sup> on day 1 (maximum dose: 15 mg) in combination with capecitabine and radiation therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25167226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25167226'])">Ref</a></span>) <b>or</b> 12 mg/m<sup>2</sup> on day 1 (maximum dose: 20 mg) in combination with capecitabine and radiation therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24885554']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24885554'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3810c766-bd22-4b38-a74f-83d570ec742e">Bladder cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bladder cancer (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Muscle invasive:</b>
<b>IV</b> (mitomycin injection solution): 12 mg/m<sup>2</sup> on day 1 (in combination with fluorouracil and radiation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22512481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22512481'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Nonmuscle invasive (off-label route):</b> Intravesicular instillation of mitomycin injection solution:</p>
<p style="text-indent:-2em;margin-left:6em;">Low risk of recurrence (uncomplicated): <b>Intravesical</b>
<b>ar instillation: </b>40 mg as a single dose postoperatively; retain in bladder for 1 to 2 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17993339','lexi-content-ref-24053153']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17993339','lexi-content-ref-24053153'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Increased risk of recurrence: <b>Intravesical</b>
<b>ar instillation: </b>20 mg weekly for 6 weeks, followed by 20 mg monthly for 3 years; retain in bladder for 1 to 2 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17383080']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17383080'])">Ref</a></span>) <b>or </b>40 mg weekly for 6 weeks (with urine alkalinization and decreased urine volume to increase drug concentration); retain in bladder for 2 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11309436']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11309436'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="abc28755-296d-44c6-8865-b968961e4811">Cervical cancer, recurrent or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cervical cancer, recurrent or metastatic (off-label use; based on limited data): IV:</b> 6 mg/m<sup>2</sup> on day 1 once every 4 weeks (in combination with cisplatin) for a minimum of 2 cycles (preferably 9 cycles) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11527687']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11527687'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0941e1ee-82d0-48a1-a4ca-aa05a3115959">Gastric cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric cancer: Note:</b> Although FDA approved for the treatment of disseminated adenocarcinoma of the stomach and as palliative treatment, mitomycin use has been replaced by other agents. Current guidelines for the management of gastric cancer do not include recommendations for the use of mitomycin in the treatment of this condition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35914639']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35914639'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> 20 mg/m<sup>2</sup> once every 6 to 8 weeks; discontinue if disease progression continues after 2 courses of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing: </i>
<b>IV:</b> 7 mg/m<sup>2</sup> (maximum dose: 14 mg) once every 6 weeks for 4 cycles (in combination with cisplatin and fluorouracil) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11956258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11956258'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f2c759a1-81e9-4934-b4d3-db45c2e91c7c">Hepatocellular cancer, chemoembolization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatocellular cancer, chemoembolization (off-label use): </b>Conventional transcatheter arterial chemoembolization (cTACE): <b>Intra-arterial:</b> 10 mg as a single dose via intra-arterial injection; based on clinical judgement, may repeat at 6 to 8 week intervals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31032104']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31032104'])">Ref</a></span>) <b>or</b> 8 mg/m<sup>2</sup> as a single dose via intra-arterial injection every 4 weeks for at least 2 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22265853']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22265853'])">Ref</a></span>). Refer to protocol and institutional policies for additional dosing/administration details.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c856e2c-2f61-4353-a4d1-5e5b8945caaa">Pancreatic cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic cancer: </b>
<b>Note: </b>Although FDA approved for the treatment of disseminated adenocarcinoma of the pancreas and as palliative treatment, mitomycin use has been replaced by other agents. Current guidelines for the management of metastatic pancreatic cancer do not include recommendations for the use of mitomycin in the treatment of this condition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32755482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32755482'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 20 mg/m<sup>2</sup> once every 6 to 8 weeks; discontinue if disease progression continues after 2 courses of therapy.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5d3f43c7-d977-4f7d-9c5c-4c45d94e9ec5">Vulvar cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vulvar cancer, advanced (off-label use; based on limited data): IV:</b> 15 mg/m<sup>2</sup> on day 1 every 14 days for 2 cycles (in combination with concomitant radiation and fluorouracil) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8641609']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8641609'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992079"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The manufacturer’s labeling states to avoid use in patients with serum creatinine &gt;1.7 mg/dL, although no other dosage modifications are provided. The following adjustments have been recommended:</p>
<p style="text-indent:-2em;margin-left:2em;">Krens 2019:</p>
<p style="text-indent:-2em;margin-left:4em;">GFR ≥30 mL/minute: No need for dose adjustment is expected.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &lt;30 mL/minute: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Use is not recommended.</p></div>
<div class="block doha drugH1Div" id="F50989274"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer’s labeling. However, the following adjustments have been recommended:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild or moderate impairment: No need for dose adjustment is expected (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Consider reducing dose to 50% of the original dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p></div>
<div class="block doo drugH1Div" id="F20342773"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer </i>
<i>with a BMI ≥30 kg/m<sup>2</sup></i>
<i>:</i> Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full, weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>). <b>Note:</b> Some protocols may have maximum recommended doses.</p></div>
<div class="block dot drugH1Div" id="F13895064"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hematologic toxicity (based on nadir at prior dose; according to the manufacturer’s labeling; also refer to individual protocols for dosage adjustment recommendations).</i></p>
<p style="text-indent:-2em;margin-left:4em;">Leukocytes 3,000 to &lt;4,000/mm<sup>3</sup>: Hold therapy until leukocyte count ≥4,000/mm<sup>3</sup>, then may resume 100% of prior dose in subsequent cycles.</p>
<p style="text-indent:-2em;margin-left:4em;">Leukocytes 2,000 to &lt;3,000/mm<sup>3</sup>: Hold therapy until leukocyte count ≥4,000/mm<sup>3</sup>; reduce mitomycin dose to 70% of prior dose in subsequent cycles.</p>
<p style="text-indent:-2em;margin-left:4em;">Leukocytes &lt;2,000/mm<sup>3</sup>: Hold therapy until leukocyte count ≥4,000/mm<sup>3</sup>; reduce mitomycin dose to 50% of prior dose in subsequent cycles.</p>
<p style="text-indent:-2em;margin-left:4em;">Platelets 75,000 to &lt;100,000/mm<sup>3</sup>: Hold therapy until platelets ≥100,000/mm<sup>3</sup>, then may resume 100% of prior dose in subsequent cycles.</p>
<p style="text-indent:-2em;margin-left:4em;">Platelets 25,000 to &lt;75,000/mm<sup>3</sup>: Hold therapy until platelets ≥100,000/mm<sup>3</sup>; reduce mitomycin dose to 70% of prior dose in subsequent cycles.</p>
<p style="text-indent:-2em;margin-left:4em;">Platelets &lt;25,000/mm<sup>3</sup>: Hold therapy until platelets ≥100,000 mm<sup>3</sup>; reduce mitomycin dose to 50% of prior dose in subsequent cycles.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Nonhematologic toxicity:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Pulmonary toxicity: Discontinue mitomycin if pulmonary toxicity occurs and other potential etiologies have been ruled out.</p></div>
<div class="block doe drugH1Div" id="F13895061"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F13895032"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (14%), nausea (14%), vomiting (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bone marrow depression (64%; onset: 4 weeks; recovery: 8 to 10 weeks), hemolytic-uremic syndrome (HUS; ≤15%), thrombotic thrombocytopenic purpura (TTP; ≤15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (14%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Mucous membrane disease (toxicity: 4%), stomatitis (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Adult respiratory distress syndrome (ARDS), bladder spasm (intravesical administration), cardiac failure, dyspnea, extravasation reactions, fibrosis (bladder; intravesical administration), hepatic sinusoidal obstruction syndrome (formerly known as hepatic veno-occlusive disease), interstitial fibrosis, malaise, nonproductive cough, pulmonary infiltrates, renal failure (irreversible), skin rash, weakness</p></div>
<div class="block coi drugH1Div" id="F13895029"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to mitomycin or any component of the formulation; thrombocytopenia; coagulation disorders, or other increased bleeding tendency.</p></div>
<div class="block war drugH1Div" id="F13895030"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bladder fibrosis/contraction: Bladder fibrosis/contraction has been reported with intravesical administration (unlabeled administration route).</p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Bone marrow suppression (thrombocytopenia and leukopenia) is common and may be severe and/or contribute to infections. WBC and platelet nadir usually occurs at 4 weeks, although may occur at up to 8 weeks; recovery occurs within 10 weeks. Fatalities due to sepsis have been reported. Myelosuppression is dose-limiting, delayed in onset, and cumulative.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Mitomycin is a potent vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation. May cause necrosis and tissue sloughing; delayed erythema and/or ulceration have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: In a scientific statement from the American Heart Association, mitomycin has been determined to be an agent that may either cause reversible direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemolytic-uremic syndrome: Hemolytic-uremic syndrome (HUS) has been reported (incidence not defined); condition usually involves microangiopathic hemolytic anemia (hematocrit ≤25%), thrombocytopenia (≤100,000/mm<sup>3</sup>), and irreversible renal failure (serum creatinine ≥1.6 mg/dL). HUS may occur at any time (either with single agent or combination therapy), is generally associated with single doses ≥60 mg, and HUS symptoms may be exacerbated by blood transfusion. Other less common effects may include pulmonary edema, neurologic abnormalities, and hypertension. A high mortality from HUS has been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Cases of acute respiratory distress syndrome (ARDS) have been reported in patients receiving mitomycin in combination with other chemotherapy who were maintained at FIO<sub>2</sub> concentrations &gt;50% perioperatively; use caution to provide only enough oxygen to maintain adequate arterial saturation and avoid overhydration. Pulmonary toxicity has also been reported as dyspnea with nonproductive cough and appearance of pulmonary infiltrates on radiograph.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Vinca alkaloids: Shortness of breath and bronchospasm have been reported in patients receiving vinca alkaloids in combination with mitomycin or who received mitomycin previously; this acute respiratory distress has occurred within minutes to hours following the vinca alkaloid; may be managed with bronchodilators, steroids and/or oxygen.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Product selection: Mitomycin is available as mitomycin for injection, mitomycin (ophthalmic), and mitomycin (ureteral gel); the products are different and are <b>NOT</b> interchangeable. Verify product label prior to reconstitution and administration to prevent medication errors.</p></div>
<div class="block foc drugH1Div" id="F13895083"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mutamycin: 5 mg (1 ea); 20 mg (1 ea); 40 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg (1 ea); 20 mg (1 ea); 40 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg (1 ea); 20 mg (1 ea); 40 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F13895017"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16570436"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (mitoMYcin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $180.00 - $291.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $132.00 - $758.40</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $264.00 - $1,516.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Mutamycin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $423.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $1,101.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $2,202.35</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871439"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg ([DSC]); 20 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F13895066"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer by slow IV push/bolus via a freely-running saline infusion. Consider using a central venous catheter.</p>
<p style="text-indent:-2em;margin-left:4em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Initiate dimethyl sulfate (DMSO) antidote. Apply dry cold compress for 20 minutes 4 times/day for 1 to 2 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>DMSO:</i> Apply topically to a region covering twice the affected area every 8 hours for 7 days; begin within 10 minutes of extravasation; do not cover with a dressing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intravesicular administration of mitomycin injection solution (off-label use/route):</b> Instill into bladder and retain for 1 to 2 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11309436','lexi-content-ref-17383080','lexi-content-ref-17993339','lexi-content-ref-24053153']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11309436','lexi-content-ref-17383080','lexi-content-ref-17993339','lexi-content-ref-24053153'])">Ref</a></span>); rotate patient every 15 to 30 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-arterial:</b> Transcatheter arterial chemoembolization (TACE; off-label use): For conventional TACE, mitomycin was administered with lipiodol and contrast media followed by particle embolization with an embolic agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31032104']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31032104'])">Ref</a></span>) or followed by starch microspheres for vessel occlusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22265853']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22265853'])">Ref</a></span>). IV antibiotics were administered prior to the procedure and embolic material was injected through the catheter until hemostasis was achieved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22280845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22280845'])">Ref</a></span>). Refer to protocol and institutional policies for additional administration details.</p></div>
<div class="block hazard drugH1Div" id="F49132773"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F13895022"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric cancer:</b> Treatment of disseminated adenocarcinoma of the stomach (in combination with other chemotherapy agents) and as palliative treatment when other modalities have failed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Although FDA approved for the treatment of disseminated adenocarcinoma of the stomach and as palliative treatment, mitomycin use in the management of gastric cancer has been replaced by other agents. Current guidelines for the management of gastric cancer do not include recommendations for the use of mitomycin in the treatment of this condition (ESMO [Lordick 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic cancer:</b> Treatment of disseminated adenocarcinoma of the pancreas (in combination with other chemotherapy agents) and as palliative treatment when other modalities have failed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Although FDA approved for the treatment of disseminated adenocarcinoma of the pancreas and as palliative treatment, mitomycin use in the management of pancreatic cancer has been replaced by other agents. Current guidelines for the management of metastatic pancreatic cancer do not include recommendations for the use of mitomycin in the treatment of this condition (ASCO [Sohal 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Not recommended for single-agent primary therapy or to replace appropriate surgery and/or radiotherapy in the treatment of these conditions.</p></div>
<div class="block off-label drugH1Div" id="F25716198"><span class="drugH1">Use: Off-Label: Adult</span><p>Anal cancer; Bladder cancer; Cervical cancer, recurrent or metastatic; Hepatocellular carcinoma (chemoembolization); Vulvar cancer, advanced</p></div>
<div class="block mst drugH1Div" id="F13895009"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">MitoMYcin (Systemic) may be confused with MitoMYcin (Ophthalmic), MitoMYcin (ureteral gel), mitotane, mitoXANTRONE</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">MitoMYcin is available as mitoMYcin for injection, mitoMycin (ophthalmic), and mitoMYcin (ureteral gel); the products are different and are NOT interchangeable. Verify product label prior to reconstitution and administration to prevent medication errors.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13895039"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F13895037"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antineoplastic Agents (Vinca Alkaloids): May enhance the adverse/toxic effect of MitoMYcin (Systemic). Specifically, the risk of pulmonary toxicity may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F57851981"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Mitomycin is expected to have a low risk of treatment-related azoospermia and male infertility (ESMO [Lambertini 2020]).</p></div>
<div class="block pri drugH1Div" id="F13895025"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F13895028"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if mitomycin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer.</p></div>
<div class="block mop drugH1Div" id="F13895071"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor CBC with differential (repeatedly during therapy and for ≥8 weeks following therapy); serum creatinine; pulmonary function tests. Monitor for signs/symptoms of HUS, pulmonary toxicity, and infection. Monitor infusion site.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F13895050"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Mitomycin alkylates DNA to produce DNA cross-linking (primarily with guanine and cytosine pairs) and inhibits DNA and RNA synthesis. Mitomycin is not cell cycle specific but has its maximum effect against cells in late G and early S phases (Perry 2012).</p></div>
<div class="block phk drugH1Div" id="F13895052"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 17 minutes (30 mg dose)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (primarily [Perry 2012]); Urine</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F13895087"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Asomutan | Crisofimina | Mitokebir | Mitomicina | Mitomicina C | Mitomicina Gobbi | Mitomicina martian | Mitomicina microsules | Mitomicina-c filaxis | Mitomycin c bristol | Mitotie | Ronzine | Vetio</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin c kyowa | Mitomycin medac</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin omegapharm</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin c kyowa</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin C</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Mitocin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Mitem</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Fatrix | Metomit | Mitomicina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin-c</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Al phamycina | Mitolem | Mitomicina | Mixandex | Mutamycin | Riptan</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin accord | Mitomycin C | Mitomycin medac</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ametycine | Mitem | Mito | Mito Medac | Mitomycin accord | Mitomycin AKO | Mitomycin hexal | Mitomycin Teva | Urocin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Mitomicina kemex | Mitotie</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Mito | Mitomycin accord | Mitomycin medac | Mitomycin-c kyowa | Mutamycin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Mutamycin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Mitomicina accord | Mitomicina medac | Mitomycin C</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin accord | Mitomycin medac | Mitomycin Substipharm | Mitostat | Mutamycin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ametycine | Mitomycin medac | Mitomycine accord | Mitomycine Dci | Mitomycine substipharm</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Mitocin | Mitomycin c kyowa | Mitomycin medac</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin c kyowa</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin c kyowa | Mitomycin medac</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin-c</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin c kyowa</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin C</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Almito | Lyomit | Mito | Mitomycin c kyowa | Mitonco</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Mitomicina medac | Mitomycin C | Miturox</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin C | Mitomycin C koreaunited | Mitomycin c kyowa | Mitomycin-c</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin C</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin C | Mitomycin medac | Mutamycin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Mito | Mitomycin C | Mitomycin medac</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Mitolem | Mitomicina | Mitotie | Mixandex</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin c kyowa</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin c kyowa | Mitomycin-c kyowa | Mitomycine accord | Mitomycine medac</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Mito | Mitocin | Mitomycin C | Mitomycin medac | Mutamycin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Arrow Mitomycin C | Mitomycin c kyowa</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Mitomicina | Mitomycin C</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin C | Mitomycin-c kyowa</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Mitocin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Lyomit | Mito | Mito Medac | Mitomycin accord | Mitomycin C</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Jelmyto | Mitosol | Mutamycin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Mitomicina | Mitomicina C Kyowa | Mitomicina medac</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Maximiton | Mitokebir | Mitomicina c filaxis | Mitomicina c microsules | Mitomicina c tuteur | Mitomicina fapasa | Mitomicina farmaco uruguayo | Mitomicina martian | Mitomicina sidus | Mitotie</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin C | Mutamycin | Vero mitomycin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin medac</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin medac | Mitomycin Substipharm</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin C</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Mitem | Mitomicin medac | Mitomycin c aesica | Mitomycin c inbsa | Mitomycin c kyowa | Mutamycin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin C | Mitomycin medac</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin-c kyowa | Vesimycin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Ametycine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Misintu | Mitomycin C</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin-c | Mitonco | Vesimycin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Mitolem | Mitomycin c kyowa | Mitomycin Mili</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Mitomicina C | Mitomicina c filaxis | Mitomicina delta Farma | Mutamycin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Mitomycin C</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.2020">
<a name="USP.2020"></a>&lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18430910">
<a name="18430910"></a>Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. <i>JAMA.</i> 2008;299(16):1914-1921. doi:10.1001/jama.299.16.1914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/18430910/pubmed" id="18430910" target="_blank">18430910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 101.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11309436">
<a name="11309436"></a>Au JL, Badalament RA, Wientjes MG, et al; International Mitomycin C Consortium. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. <i>J Natl Cancer Inst.</i> 2001;93(8):597-604.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/11309436/pubmed" id="11309436" target="_blank">11309436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9164216">
<a name="9164216"></a>Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. <i>J Clin Oncol</i>. 1997;15(5):2040-2049.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/9164216/pubmed" id="9164216" target="_blank">9164216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28456635">
<a name="28456635"></a>Chang SS, Bochner BH, Chou R, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline [published correction appears in <i>J Urol</i>. 2017;198(5):1175]. <i>J Urol.</i> 2017;198(3):552-559. doi: 10.1016/j.juro.2017.04.086<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/28456635/pubmed" id="28456635" target="_blank">28456635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27317986">
<a name="27317986"></a>Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. <i>J Urol</i>. 2016;196(4):1021-1029.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/27317986/pubmed" id="27317986" target="_blank">27317986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8823332">
<a name="8823332"></a>Flam M, John M, Pajak TF, et al, “Role of Mitomycin in Combination With Fluorouracil and Radiotherapy, and of Salvage Chemoradiation in the Definitive Nonsurgical Treatment of Epidermoid Carcinoma of the Anal Canal: Results of a Phase III Randomized Intergroup Study,” <i>J Clin Oncol</i>, 1996, 14(9):2527-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/8823332/pubmed" id="8823332" target="_blank">8823332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17383080">
<a name="17383080"></a>Friedrich MG, Pichlmeier U, Schwaibold H, et al, “Long-Term Intravesical Adjuvant Chemotherapy Further Reduces Recurrence Rate Compared With Short-Term Intravesical Chemotherapy and Short-Term Therapy With Bacillus Calmette-Guérin (BCG) in Patients With Non-Muscle-Invasive Bladder Carcinoma,” Eur Urol, 2007, 52(4):1123-29.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/17383080/pubmed" id="17383080" target="_blank">17383080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. Published online May 3, 2021. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17993339">
<a name="17993339"></a>Hall MC, Chang SS, Dalbagni G, et al, “Guideline for the Management of Nonmuscle Invasive Bladder Cancer (stages Ta, T1, and Tis): 2007 Update,” <i>J Urol</i>, 2007, 178(6):2314-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/17993339/pubmed" id="17993339" target="_blank">17993339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22512481">
<a name="22512481"></a>James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. <i>N Engl J Med</i>. 2012;366(16):1477-1488.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/22512481/pubmed" id="22512481" target="_blank">22512481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23578724">
<a name="23578724"></a>James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. <i>Lancet Oncol</i>. 2013;14(6):516-524. doi:10.1016/S1470-2045(13)70086-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/23578724/pubmed" id="23578724" target="_blank">23578724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32976936">
<a name="32976936"></a>Lambertini M, Peccatori FA, Demeestere I, et al; ESMO Guidelines Committee. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines. <i>Ann Oncol</i>. 2020;31(12):1664-1678. doi:10.1016/j.annonc.2020.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/32976936/pubmed" id="32976936" target="_blank">32976936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8641609">
<a name="8641609"></a>Landoni F, Maneo A, Zanetta G, et al. Concurrent preoperative chemotherapy with 5-fluorouracil and mitomycin C and radiotherapy (FUMIR) followed by limited surgery in locally advanced and recurrent vulvar carcinoma. <i>Gynecol Oncol</i>. 1996;61(3):321-327.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/8641609/pubmed" id="8641609" target="_blank">8641609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35914639">
<a name="35914639"></a>Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. <i>Ann Oncol.</i> 2022;33(10):1005-1020. doi:10.1016/j.annonc.2022.07.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/35914639/pubmed" id="35914639" target="_blank">35914639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12118027">
<a name="12118027"></a>Maisey N, Chau I, Cunningham D, et al. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. <i>J Clin Oncol.</i> 2002;20(14):3130-3136. doi:10.1200/JCO.2002.09.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/12118027/pubmed" id="12118027" target="_blank">12118027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25167226">
<a name="25167226"></a>Meulendijks D, Dewit L, Tomasoa NB, et al. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. <i>Br J Cancer</i>. 2014;111(9):1726-1733.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/25167226/pubmed" id="25167226" target="_blank">25167226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mitomycin.1">
<a name="Mitomycin.1"></a>Mitomycin [prescribing information]. Durham, NC: Accord Healthcare Inc; May 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mitomycin.2">
<a name="Mitomycin.2"></a>Mitomycin [product monograph]. Mississauga, Ontario, Canada: Hikma Canada Limited; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22280845">
<a name="22280845"></a>Morse MA, Hanks BA, Suhocki P, et al. Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma. <i>Clin Colorectal Cancer</i>. 2012;11(3):185-190. doi: 10.1016/j.clcc.2011.11.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/22280845/pubmed" id="22280845" target="_blank">22280845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mutamycin.1">
<a name="Mutamycin.1"></a>Mutamycin (mitomycin) [prescribing information]. Durham, NC: Accord Biopharma Inc; September 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20354531">
<a name="20354531"></a>Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). <i>Br J Cancer</i>. 2010;102(7):1123-1128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/20354531/pubmed" id="20354531" target="_blank">20354531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24053153">
<a name="24053153"></a>O'Brien T, Ray E, Chatterton K, et al. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer. <i>BJU Int</i>. 2013;112(8):1096-1104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/24053153/pubmed" id="24053153" target="_blank">24053153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22997449">
<a name="22997449"></a>Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al. Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines. <i>Ann Oncol.</i> 2012;23(suppl 7):167-173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/22997449/pubmed" id="22997449" target="_blank">22997449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Perry.1">
<a name="Perry.1"></a>Perry MC. Chemotherapeutic agents: Mitomycin. <i>The Chemotherapy Source Book</i>. 5th ed. Philadelphia, PA: 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11956258">
<a name="11956258"></a>Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. <i>J Clin Oncol</i>. 2002;20(8):1996-2004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/11956258/pubmed" id="11956258" target="_blank">11956258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32755482">
<a name="32755482"></a>Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2020:JCO2001364. doi:10.1200/JCO.20.01364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/32755482/pubmed" id="32755482" target="_blank">32755482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24885554">
<a name="24885554"></a>Thind G, Johal B, Follwell M, et al. Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma. <i>Radiat Oncol</i>. 2014;9:124.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/24885554/pubmed" id="24885554" target="_blank">24885554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8874455">
<a name="8874455"></a>UKCCCR. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. <i>Lancet</i>. 1996;348(9034):1049-1054.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/8874455/pubmed" id="8874455" target="_blank">8874455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 24, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22265853">
<a name="22265853"></a>Vogl TJ, Naguib NN, Nour-Eldin NE, et al. Retrospective study on the use of different protocols for repeated transarterial chemoembolization in the treatment of patients with hepatocellular carcinoma. <i>Acad Radiol</i>. 2012;19(4):434-439. doi: 10.1016/j.acra.2011.12.009.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/22265853/pubmed" id="22265853" target="_blank">22265853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11527687">
<a name="11527687"></a>Wagenaar HC, Pecorelli S, Mangioni C, et al. Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study. <i>Eur J Cancer</i>. 2001;37(13):1624-1628.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/11527687/pubmed" id="11527687" target="_blank">11527687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31032104">
<a name="31032104"></a>Yamada R, Bassaco B, Bracewell S, et al. Long-term follow-up after conventional transarterial chemoembolization (c-TACE) with mitomycin for hepatocellular carcinoma (HCC). <i>J Gastrointest Oncol</i>. 2019;10(2):348-353. doi: 10.21037/jgo.2019.01.01.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitomycin-intravenous-and-intravesical-systemic-drug-information/abstract-text/31032104/pubmed" id="31032104" target="_blank">31032104</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 83318 Version 302.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
